Nature 2000, 407:762–764.PubMedCrossRef 10. Mah TF, O’Toole GA: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001, 9:34–39.PubMedCrossRef LY3039478 concentration 11. Palmer KL, Mashburn LM, Singh PK,

Whiteley M: Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 2005, 187:5267–5277.PubMedCrossRef 12. Sriramulu DD, Lünsdorf H, Lam JS, Römling U: Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic brosis lung. J Med Microbiol 2005, 54:667–676.PubMedCrossRef 13. Matsui H, Wagner VE, Hill DB, Schwab UE, Rogers TD, Button B, Taylor RM, Superfine R, Rubinstein M, Iglewski BH, Boucher RC: A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci USA 2006, 103:18131–18136.PubMedCrossRef 14. Sulakvelidze A, Alavidze Z, Morris JG: Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45:649–659.PubMedCrossRef 15. Ceyssens P, Miroshnikov K, Mattheus W, Krylov V, Robben J, Noben J, Vanderschraeghe S, Sykilinda N, Kropinski A, Volckaert G, Mesyanzhinov V, Lavigne R: Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa . Environ Microbiol 2009, 11:2874–2883.PubMedCrossRef 16. Krylov VN, Tolmachova TO, Akhverdian VZ: DNA homology in species of

bacteriophages active on Thiazovivin order Pseudomonas aeruginosa . Arch Virol 1993, 131:141–151.PubMedCrossRef 17. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Parys LV, Lavigne R, Volckaert G, Mattheus W, Verween G, Corte PD, Rose T, Jennes S, Zizi M, Vos DD, Vaneechoutte M: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 2009, 4:e4944.PubMedCrossRef

18. Skurnik M, Strauch E: Phage therapy: facts and fiction. Int J Med Microbiol 2006, 296:5–14.PubMedCrossRef 19. Levin BR, Bull JJ: Population and evolutionary dynamics Reverse transcriptase of phage therapy. Nat Rev Micro 2004, 2:166–173.CrossRef 20. Martin DW, Schurr MJ, Mudd MH, Govan JR, Holloway BW, Deretic V: Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 1993, 90:8377–8381.PubMedCrossRef 21. Hassett DJ, Sutton MD, Schurr MJ, Herr AB, Selleckchem Vistusertib Caldwell CC, Matu JO: Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol 2009, 17:130–138.PubMedCrossRef 22. Ackermann HW: 5500 Phages examined in the electron microscope. Arch Virol 2007, 152:227–243.PubMedCrossRef 23. Budzik JM, Rosche WA, Rietsch A, O’Toole GA: Isolation and characterization of a generalized transducing phage for Pseudomonas aeruginosa strains PAO1 and PA14. J Bacteriol 2004, 186:3270–3273.PubMedCrossRef 24.